MAM
PBYI icon

Melqart Asset Management’s Puma Biotechnology PBYI Stock Holding History

Melqart Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-275,000
Closed -$12.6M – 26
2018
Q3 		$12.6M Hold
275,000
– – 1.18% 21
2018
Q2 		$16.3M Buy
+275,000
New +$15.9M 1.39% 20

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Melqart Asset Management's PBYI Position: Q4 2019 in Review

Melqart Asset Management sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 529,112 shares — an estimated $5.7M sold.

Melqart Asset Management first reported a position in PBYI in Q2 2018 and held it in 4 quarters. The position peaked at $23.6M in Q4 2018. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

  • Melqart Asset Management reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
  • Melqart Asset Management sold 529,112 Puma Biotechnology shares in Q4 2019, an estimated $5.7M.
  • Melqart Asset Management first reported a position in Puma Biotechnology in Q2 2018 and held it in 4 quarters.
  • Melqart Asset Management's Puma Biotechnology position peaked at $23.6M in Q4 2018.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Melqart Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.